List of Excipients in Branded Drug HELIUM/OXYGEN MIXTURE 80/20

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
General Air Service & Supply Co	HELIUM/OXYGEN MIXTURE 80/20	helium/oxygen mixture 80/20	21220-155	HELIUM

Helium/Oxygen 80/20 Mixture: Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: August 28, 2026

Helium/oxygen 80/20, commonly called heliox 80/20, is a medical gas mixture rather than a conventional drug product. Helium and oxygen are the active inhaled components; the formulation has no conventional excipient. Commercial value is concentrated in gas purity, blending accuracy, cylinders, valves, delivery systems, supply reliability, and clinical positioning.

The composition itself is likely to have weak patentability because helium-oxygen respiratory mixtures and heliox therapy have been publicly known for decades. The stronger intellectual-property opportunities are in delivery devices, closed-loop concentration control, portable systems, humidification, monitoring, manufacturing quality systems, and clinical methods with defined patient-selection criteria.

What is helium/oxygen 80/20 used for?

Heliox 80/20 contains approximately 80% helium and 20% oxygen by volume. Its principal therapeutic rationale is helium's lower density relative to nitrogen-containing air. Lower gas density can reduce turbulent airflow resistance in narrowed upper or lower airways.

Potential clinical applications include:

• Acute upper-airway obstruction
• Croup and post-extubation stridor
• Severe asthma with airflow limitation
• Chronic obstructive pulmonary disease exacerbations
• Bronchiolitis and selected pediatric respiratory conditions
• Difficult airway management
• Respiratory therapy and pulmonary-function testing

The 20% oxygen concentration is below room air's approximately 21% oxygen concentration. Heliox 80/20 therefore should not be treated as an oxygen-enrichment product. It may be unsuitable for patients requiring supplemental oxygen to correct hypoxemia. Clinical use normally requires oxygenation monitoring and a delivery system capable of maintaining the intended mixture.

Heliox is generally used as an adjunct to other treatment, not as a substitute for bronchodilators, corticosteroids, antibiotics, airway intervention, or mechanical ventilation.

Is helium/oxygen 80/20 an FDA-approved drug?

A helium/oxygen 80/20 mixture does not have the same regulatory profile as a conventional FDA-approved small-molecule drug with an NDA, labeled indication, and Orange Book patent listing.

FDA regulatory status

The FDA regulates medical gases as drugs when they are intended for use in diagnosis, cure, mitigation, treatment, or prevention of disease. The Federal Food, Drug, and Cosmetic Act and FDA medical-gas rules address production, labeling, container systems, current good manufacturing practice, and distribution requirements.[1][2]

A commercial 80/20 heliox product may be marketed as a medical gas if it satisfies applicable requirements for:

• Identity and composition
• Strength and concentration
• Purity
• Manufacturing controls
• Cylinder and closure integrity
• Labeling
• Stability and expiration dating
• Adulteration and misbranding controls
• Distribution and complaint handling

The key regulatory issue is product-specific authorization and labeling. A manufacturer cannot assume that historical clinical use creates approval for every indication or delivery configuration.

Is heliox listed in the Orange Book?

The Orange Book lists patents and exclusivity associated with FDA-approved drug products that meet applicable listing requirements. A standalone 80/20 heliox mixture should not be expected to have a conventional Orange Book patent estate unless a sponsor has obtained an applicable FDA approval and listed qualifying patents.[3]

For most commercial purposes, the relevant regulatory records are more likely to involve:

• Medical-gas manufacturing registration
• Drug establishment registration
• Product listing
• FDA inspections
• Labeling and quality documentation
• Device clearances for regulators, mixers, ventilator interfaces, and delivery systems

What excipients are used in helium/oxygen 80/20?

The mixture has no conventional excipient strategy. Helium and oxygen are the product's active components.

Product element	Role	Excipient status
Helium	Reduces gas density and airflow resistance	Active component
Oxygen	Supports oxygen delivery and determines oxygen concentration	Active component
Nitrogen	Usually absent or controlled as an impurity	Not an intended excipient
Water vapor	May be introduced through humidification equipment	Device-delivered adjunct, not usually a formulation excipient
Lubricants, seals, cylinder coatings	Support container function	Packaging or device materials
Propellants or preservatives	Not used	Not applicable

The principal formulation controls are therefore gas composition and impurity limits. A commercially meaningful specification should address oxygen concentration, helium concentration, moisture, hydrocarbons, carbon monoxide, carbon dioxide, nitrogen, particulate matter, pressure, and container integrity.

USP and compendial gas standards can influence identity, purity, testing, and labeling requirements. The relevant standards depend on the product's intended market, gas grade, container configuration, and regulatory pathway.[4]

What formulation and manufacturing patents protect heliox products?

The 80/20 composition is unlikely to provide a strong standalone patent position. A claim directed broadly to a helium-oxygen respiratory mixture at or near 80/20 would face prior-art risks from longstanding medical use, respiratory therapy publications, and earlier gas-mixture disclosures.

Patentable technology categories

Technology category	Patent potential	Commercial relevance
Helium/oxygen ratio alone	Low	Weak exclusionary position
Narrow concentration ranges tied to a defined indication	Low to moderate	May support method claims if clinical benefit is demonstrated
Inline blending and concentration control	Moderate	Supports manufacturing and point-of-care systems
Portable heliox delivery	Moderate to strong	Supports emergency, ambulance, home-care, and transport use
Ventilator integration	Moderate to strong	Can create device-specific barriers
Closed-loop oxygen/helium monitoring	Moderate to strong	Improves safety and concentration accuracy
Humidification compatible with helium-rich gas	Moderate	Addresses comfort and airway management
Leak-resistant cylinders and regulators	Moderate	Supports operational performance
Manufacturing and filling processes	Moderate	Can protect throughput, purity, and yield
Patient-selection or dosing protocols	Variable	Method-of-use protection may be possible
Combination with aerosolized drugs	Variable	May support device or treatment-method claims

A practical patent strategy should focus on a platform rather than the gas ratio. Potential claim sets include:

1. A system that blends helium and oxygen in real time.
2. A controller that maintains oxygen concentration within a defined range despite flow changes.
3. A portable cylinder or cartridge architecture optimized for helium retention.
4. A delivery circuit that limits dilution with ambient air.
5. A ventilator or nebulizer system calibrated for helium-rich gas.
6. A humidification system that preserves target composition.
7. A method for treating a defined obstruction phenotype using heliox and a specified flow regime.
8. A monitoring algorithm that detects concentration drift, leaks, or incorrect cylinder connection.

Patent term for newly filed utility patents is generally 20 years from the earliest effective nonprovisional filing date, subject to patent-term adjustment and any applicable regulatory extension.[5] The economic life of a heliox product will more likely depend on manufacturing know-how, supply contracts, device integration, and regulatory execution than on composition claims.

How strong is the patent estate for helium/oxygen 80/20?

The patent estate is weak for the basic mixture and potentially stronger for enabling technology.

Asset	Estimated strength	Reason
80/20 composition	Low	Longstanding public use and predictable formulation
Heliox for respiratory distress generally	Low	Broad clinical concept is established
Specific patient subgroup	Moderate	Depends on clinical data and claim precision
Integrated delivery device	Moderate to strong	Functionality and engineering may be differentiated
Automated gas blending	Moderate	Patentability depends on architecture and prior art
Cylinder and valve system	Moderate	Commercial value depends on performance and compatibility
Manufacturing process	Moderate	Trade secrets may be more valuable than patents
Hospital workflow and service model	Low patent strength	Better protected through contracts and operations

Freedom-to-operate analysis should separate the gas composition from the delivery system. A company may have freedom to sell the mixture while infringing a third party's claims covering a regulator, ventilator interface, humidifier, gas mixer, or monitoring algorithm.

When does helium/oxygen 80/20 lose exclusivity?

The basic 80/20 mixture has no apparent composition-based exclusivity period comparable to a new chemical entity. Its commercial exclusivity is established through operational assets rather than regulatory exclusivity.

Exclusivity timeline

Exclusivity mechanism	Relevance to 80/20 heliox
New chemical entity exclusivity	Generally not applicable
Orphan-drug exclusivity	Possible only for an eligible approved indication; not inherent in the mixture
New clinical investigation exclusivity	Depends on FDA approval and statutory criteria
Orange Book-listed patents	Not expected without a qualifying approved drug product
Device patents	Potentially relevant to delivery and monitoring systems
Trade secrets	Highly relevant to filling, testing, logistics, and quality systems
Supply contracts	Important in hospital and distributor channels
Regulatory know-how	Commercially relevant but not statutory exclusivity

A sponsor seeking durable market protection should combine regulatory approvals, proprietary hardware, validated manufacturing, hospital contracts, and targeted patents.

What generic entry risks exist for heliox 80/20?

Generic entry risk is high for the gas mixture and lower for integrated systems.

Gas-product entry

A competitor with access to medical-grade helium and oxygen can potentially manufacture an equivalent mixture if it can meet applicable quality, packaging, and regulatory requirements. The product may be particularly vulnerable to:

• Low switching costs for hospitals with standard regulators
• Limited formulation complexity
• Multiple industrial-gas suppliers
• Contract filling
• Regional cylinder exchange networks
• Hospital pharmacy or respiratory-therapy substitution

System-product entry

Entry barriers increase when the product includes:

• Proprietary mixer hardware
• Certified ventilator integration
• Automated oxygen monitoring
• Specialized pediatric interfaces
• Disposable circuits
• Transport or ambulance packaging
• Validated nebulizer compatibility
• Software-controlled concentration maintenance

The most defensible commercial package is a regulated delivery system with clinical workflow integration, rather than a cylinder containing an undifferentiated gas mixture.

Which companies compete in medical helium and oxygen supply?

The competitive landscape is driven by industrial and medical-gas infrastructure. Relevant multinational suppliers include Linde, Air Liquide, Air Products, and Messer. Regional medical-gas companies, hospital gas-service providers, and contract fillers can compete in individual markets.

Competition depends on:

• Helium sourcing and allocation
• Cylinder fleet size
• Filling capacity
• Hospital distribution contracts
• Emergency delivery capabilities
• Regulator and connector compatibility
• Quality-system maturity
• Reimbursement and hospital procurement rules

Helium supply is strategically important. Medical-gas companies may face higher input costs, allocation constraints, and transportation losses because helium is scarce, difficult to retain, and more prone to leakage than heavier gases.

What commercial opportunities exist for helium/oxygen 80/20?

Acute-care respiratory therapy

Hospitals can use heliox in emergency departments, pediatric units, intensive-care units, and respiratory-therapy departments. The commercial opportunity is strongest where the product is paired with protocols, dedicated equipment, and rapid availability.

Transport medicine

Portable heliox systems could target ambulances, air transport, emergency response, and interfacility transfers. Product design priorities include low weight, pressure stability, connector standardization, and resistance to ambient-air dilution.

Pediatric and airway-focused systems

Pediatric applications may support premium positioning if the system provides controlled flow, low dead space, age-specific interfaces, and clear concentration monitoring. A sponsor would need clinical evidence and labeling appropriate to the intended population.

Device-enabled respiratory care

The highest-value opportunity may be a system that combines:

• Heliox cylinder or cartridge
• Flow regulator
• Oxygen analyzer
• Nebulizer compatibility
• Humidification
• Alarm functions
• Disposable patient circuit
• Electronic usage monitoring

This structure creates recurring revenue from disposables, service, calibration, and replacement components.

Pulmonary-function testing

Helium-containing gases are used in pulmonary testing and gas-volume measurement. This market is distinct from acute respiratory therapy and may support specialized mixtures, certified testing gases, and instrument-specific supply contracts.

Home-care use

Home use presents logistical and safety challenges. Cylinder management, caregiver training, reimbursement, oxygen monitoring, and delivery reliability may limit adoption. A compact system with concentration verification and remote service could improve feasibility, but the regulatory burden would increase with a more complex device.

What patent litigation affects helium/oxygen 80/20?

No specific patent litigation, Paragraph IV dispute, or settlement agreement is identified for the basic helium/oxygen 80/20 mixture in the cited regulatory and pharmacopeial sources.

Paragraph IV litigation is principally associated with abbreviated new drug applications that challenge listed patents for FDA-approved reference drugs. A medical-gas product without an applicable Orange Book listing would not normally generate the conventional ANDA Paragraph IV pathway.[3]

Litigation risk is more likely to arise from:

• Delivery-device patents
• Gas-mixing systems
• Ventilator integration
• Regulator and valve designs
• Medical-gas labeling
• Product liability
• Cylinder ownership and exchange rights
• Supply and exclusivity contracts

What licensing deals are relevant to heliox?

No public licensing transaction specific to the 80/20 heliox composition is identified in the cited sources. Commercial partnerships are more likely to involve:

• Hospital distribution
• Cylinder pooling
• Respiratory-device integration
• OEM supply
• Contract manufacturing
• Regional medical-gas distribution
• Clinical protocol development
• Equipment leasing and maintenance

A licensing strategy should prioritize device and software assets. Licensing the gas composition alone is unlikely to produce durable economic control.

How does heliox 80/20 compare with oxygen therapy and air?

Product	Approximate composition	Primary commercial role	Key limitation
Room air	21% oxygen, mostly nitrogen	Baseline respiratory gas	Higher density than helium mixtures
Heliox 80/20	80% helium, 20% oxygen	Reduce airflow resistance	Does not provide oxygen enrichment
Heliox 70/30	70% helium, 30% oxygen	More oxygen than 80/20	Higher helium cost; still not high-concentration oxygen
Medical oxygen	Usually high oxygen concentration	Correct hypoxemia	Does not reduce gas density
Nitrogen/oxygen blends	Air-like composition	Ventilation and testing uses	Less density reduction than heliox

The principal technical tradeoff is between helium concentration and oxygen concentration. Increasing oxygen above 20% may improve oxygen delivery but reduces the density advantage and increases oxygen-related handling requirements.

What is the revenue exposure for a heliox product?

Revenue depends more on utilization and service attachment than on the gas itself. A basic cylinder product is likely to face price competition. A system product can generate revenue from:

• Gas refills
• Cylinder rental or exchange
• Regulators
• Flowmeters
• Disposable circuits
• Pediatric masks
• Humidifiers
• Monitoring modules
• Calibration
• Preventive maintenance
• Hospital service contracts
• Clinical education

A manufacturer should model revenue by treatment episode, cylinder turnover, refill frequency, equipment utilization, and disposable attachment rate. Helium input cost and delivery losses are major gross-margin variables.

Key Takeaways

• Helium/oxygen 80/20 is a medical gas mixture, not a conventional excipient-containing drug formulation.
• Helium and oxygen are active components; conventional preservatives and excipients are not used.
• The basic 80/20 composition is likely to have weak patent protection because heliox therapy is longstanding.
• FDA compliance centers on medical-gas manufacturing, purity, labeling, containers, closures, and product-specific authorization.
• A standalone heliox product should not be expected to have a conventional Orange Book patent listing without an applicable FDA approval.
• The strongest patent opportunities are in mixers, portable delivery systems, ventilator integration, concentration monitoring, humidification, and clinical methods.
• Generic or private-label entry risk is high for the gas alone.
• Device integration, hospital contracts, cylinder logistics, quality systems, and recurring consumables can create stronger commercial barriers.
• Helium sourcing, leakage, and supply reliability are central to margin and continuity of supply.
• No specific Paragraph IV litigation, settlement, licensing deal, or composition patent is identified in the cited sources.

FAQs

Can helium/oxygen 80/20 be patented as a new drug?

A broad claim to the 80/20 mixture would face substantial prior-art challenges. Patentability is more plausible for a specific delivery system, manufacturing process, patient subgroup, or treatment protocol supported by new technical data.

Is heliox 80/20 interchangeable with medical oxygen?

No. Medical oxygen is used primarily to increase inspired oxygen concentration. Heliox 80/20 is used mainly to reduce gas density and airflow resistance, and its oxygen concentration is close to or slightly below room air.

Does a heliox manufacturer need an ANDA?

Not necessarily. The applicable pathway depends on the product's regulatory classification, approval history, labeling, and intended use. An ANDA-based Paragraph IV pathway is generally tied to an approved reference drug and Orange Book-listed patents.

What is the main manufacturing risk for 80/20 heliox?

The main risks are helium supply, concentration accuracy, leakage, cylinder compatibility, impurity control, and maintaining the specified mixture during filling, storage, transport, and delivery.

Can a company obtain orphan exclusivity for a heliox indication?

Potentially, but only if the sponsor satisfies FDA orphan-drug requirements for a qualifying rare disease or condition and obtains approval for the designated indication. The mixture itself does not automatically qualify for orphan exclusivity.

References

1. U.S. Food and Drug Administration. (2024). Medical gases. https://www.fda.gov/drugs/medical-gas/medical-gases

2. U.S. Food and Drug Administration. (2017). Current good manufacturing practice, quality control, and certain other requirements for medical gases. Federal Register, 82 Fed. Reg. 3712.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, 44th edition. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

4. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP Convention.

5. United States Patent and Trademark Office. (2024). General information concerning patents. https://www.uspto.gov/patents/basics/essentials/terms-patent-grant